AU2016261913B2 - Treatment of beta-thalassemia using ActRII ligand traps - Google Patents

Treatment of beta-thalassemia using ActRII ligand traps Download PDF

Info

Publication number
AU2016261913B2
AU2016261913B2 AU2016261913A AU2016261913A AU2016261913B2 AU 2016261913 B2 AU2016261913 B2 AU 2016261913B2 AU 2016261913 A AU2016261913 A AU 2016261913A AU 2016261913 A AU2016261913 A AU 2016261913A AU 2016261913 B2 AU2016261913 B2 AU 2016261913B2
Authority
AU
Australia
Prior art keywords
subject
certain embodiments
seq
actriib
signaling inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016261913A
Other languages
English (en)
Other versions
AU2016261913A1 (en
Inventor
Kenneth M. Attie
Jay BACKSTROM
Rajesh Chopra
Abderrahmane LAADEM
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Acceleron Pharma Inc
Original Assignee
Celgene Corp
Acceleron Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp, Acceleron Pharma Inc filed Critical Celgene Corp
Publication of AU2016261913A1 publication Critical patent/AU2016261913A1/en
Application granted granted Critical
Publication of AU2016261913B2 publication Critical patent/AU2016261913B2/en
Priority to AU2021258087A priority Critical patent/AU2021258087B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2016261913A 2015-05-13 2016-05-12 Treatment of beta-thalassemia using ActRII ligand traps Active AU2016261913B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2021258087A AU2021258087B2 (en) 2015-05-13 2021-10-29 Treatment of beta-thalassemia using ActRII ligand traps

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562161136P 2015-05-13 2015-05-13
US62/161,136 2015-05-13
US201562173836P 2015-06-10 2015-06-10
US62/173,836 2015-06-10
US201562243457P 2015-10-19 2015-10-19
US62/243,457 2015-10-19
PCT/US2016/031999 WO2016183280A1 (en) 2015-05-13 2016-05-12 Treatment of beta-thalassemia using actrii ligand traps

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021258087A Division AU2021258087B2 (en) 2015-05-13 2021-10-29 Treatment of beta-thalassemia using ActRII ligand traps

Publications (2)

Publication Number Publication Date
AU2016261913A1 AU2016261913A1 (en) 2017-11-30
AU2016261913B2 true AU2016261913B2 (en) 2021-08-12

Family

ID=57248528

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2016261913A Active AU2016261913B2 (en) 2015-05-13 2016-05-12 Treatment of beta-thalassemia using ActRII ligand traps
AU2021258087A Active AU2021258087B2 (en) 2015-05-13 2021-10-29 Treatment of beta-thalassemia using ActRII ligand traps

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2021258087A Active AU2021258087B2 (en) 2015-05-13 2021-10-29 Treatment of beta-thalassemia using ActRII ligand traps

Country Status (15)

Country Link
US (1) US20180125928A1 (enExample)
EP (1) EP3294320A4 (enExample)
JP (2) JP6976859B2 (enExample)
KR (1) KR102640198B1 (enExample)
CN (1) CN107847562A (enExample)
AU (2) AU2016261913B2 (enExample)
CA (1) CA2985777A1 (enExample)
HK (1) HK1251157A1 (enExample)
IL (2) IL284686B2 (enExample)
JO (1) JOP20160092B1 (enExample)
MY (1) MY189601A (enExample)
PH (1) PH12017502079A1 (enExample)
TN (1) TN2017000468A1 (enExample)
TW (2) TWI762444B (enExample)
WO (1) WO2016183280A1 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME00380B (me) 2005-11-23 2011-10-10 Acceleron Pharma Inc Amtagonisti aktivin-actriia i primjene za stimulaciju rasta kosti
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
LT3750552T (lt) 2008-08-14 2023-06-26 Acceleron Pharma Inc. Gdf gaudyklės
MX385318B (es) 2009-06-08 2025-03-18 Acceleron Pharma Inc Metodos para aumentar adipocitos termogenicos.
JP2012529294A (ja) 2009-06-12 2012-11-22 アクセルロン ファーマ， インコーポレイテッド 切断型ＡｃｔＲＩＩＢ−Ｆｃ融合タンパク質
EP2501400B1 (en) 2009-11-17 2017-11-01 Acceleron Pharma, Inc. Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
US9809636B2 (en) 2012-04-06 2017-11-07 Acceleron Pharma Inc. Methods for increasing red blood cell levels comprising administering BMP9
RU2018145985A (ru) 2012-11-02 2019-02-18 Селджин Корпорейшн Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений
TN2016000553A1 (en) 2014-06-13 2018-04-04 Acceleron Pharma Inc Methods and compositions for treating ulcers
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
MA41119A (fr) 2014-12-03 2017-10-10 Acceleron Pharma Inc Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
DK3227675T3 (da) 2014-12-03 2023-05-30 Celgene Corp Activin-actrii-antagonister og anvendelser til behandling af myelodysplastisk syndrom
CN108350057A (zh) 2015-05-20 2018-07-31 细胞基因公司 使用II型活化素受体配体阱的用于β-地中海贫血的体外细胞培养方法
EP3370754A4 (en) 2015-11-04 2019-10-23 Acceleron Pharma Inc. METHOD FOR INCREASING ERYTHROCYTE CONCENTRATION AND TREATMENT OF INEFFICIENT ERYTHROPOIESE
CA3005975A1 (en) 2015-11-23 2017-06-01 Acceleron Pharma Inc. Methods for treating eye disorders
RU2748278C2 (ru) 2016-07-15 2021-05-21 Акселерон Фарма Инк. Композиции и способы лечения легочной гипертензии
EA201990226A1 (ru) 2016-07-27 2019-08-30 Акселерон Фарма Инк. Способы и композиции для лечения миелофиброза
WO2018089715A1 (en) 2016-11-10 2018-05-17 Keros Therapeutics, Inc. Activin receptor type iia variants and methods of use thereof
SMT202400437T1 (it) * 2017-06-14 2024-11-15 Celgene Corp Metodi per trattare mielofibrosi associata a neoplasia mieloproliferativa e anemia
KR20250059538A (ko) 2017-11-09 2025-05-02 케로스 테라퓨틱스, 인크. 액티빈 수용체 유형 iia 변이체 및 그의 사용 방법
JP7510875B2 (ja) 2018-01-12 2024-07-04 ケロス セラピューティクス インコーポレイテッド アクチビンｉｉｂ型受容体変異体および同変異体を含む医薬組成物
EP3788065B1 (en) 2018-04-30 2025-08-27 The Children's Hospital Of Philadelphia Improving anemias by combining agents
KR20250133994A (ko) 2018-05-09 2025-09-09 케로스 테라퓨틱스, 인크. 액티빈 수용체 유형 iia 변이체 및 그의 사용 방법
KR20210088548A (ko) * 2018-10-31 2021-07-14 셀진 코포레이션 액티빈-actrii 리간드 트랩을 사용하는 고리 철적혈모구가 있는 대상체에서 매우 낮은, 낮은 또는 중간 위험 골수이형성 증후군으로 인한 빈혈의 치료
MX2022000782A (es) 2019-07-19 2022-04-18 Vifor Int Ag Inhibidores de la ferroportina para el uso en el tratamiento de la beta-talasemia dependiente de transfusiones (tdt).
CN112924684B (zh) * 2019-12-05 2022-07-29 中国科学院大连化学物理研究所 用于区分抑郁症和非抑郁症的生物标志物和包括其的诊断试剂盒
KR20230004515A (ko) 2020-03-20 2023-01-06 케로스 테라퓨틱스, 인크. 액티빈 수용체 유형 ii 키메라 및 이의 사용 방법
EP4121088A4 (en) 2020-03-20 2024-07-03 Keros Therapeutics, Inc. Methods of using activin receptor type iib variants
MX2022012610A (es) * 2020-04-13 2022-11-07 Celgene Corp Metodos para tratar anemia usando una trampa de ligando de receptor de activina de tipo iib (actriib) y fedratinib.
US12186370B1 (en) 2020-11-05 2025-01-07 Celgene Corporation ACTRIIB ligand trap compositions and uses thereof
EP4240399A4 (en) * 2020-11-06 2024-10-09 Acceleron Pharma Inc. FORMULATIONS WITH ACTRII POLYPEPTIDE VARIANTS
US20240181007A1 (en) * 2021-01-08 2024-06-06 Acceleron Pharma Inc. Compositions and methods for treating pulmonary hypertension
KR20230134476A (ko) 2021-01-20 2023-09-21 비포르 (인터내셔날) 아게 골수이형성 증후군(mds)의 치료에 사용하기 위한 페로포틴-억제제
AU2024310149A1 (en) 2023-06-26 2025-11-20 Vifor (International) Ag Ferroportin-inhibitors for the use in the treatment of hereditary haemochromatosis (hh)
WO2025122830A1 (en) * 2023-12-08 2025-06-12 Keros Therapeutics, Inc. Methods of using activin receptor type ii signaling inhibitors
WO2026041650A1 (en) 2024-08-20 2026-02-26 Vifor (International) Ag Ferroportin-inhibitors for the use in the treatment of lupus nephritis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014066486A2 (en) * 2012-10-24 2014-05-01 Celgene Corporation Biomarker for use in treating anemia

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4247A (en) * 1845-11-01 Jordan l
US6231880B1 (en) * 1997-05-30 2001-05-15 Susan P. Perrine Compositions and administration of compositions for the treatment of blood disorders
CN104524548A (zh) * 2006-12-18 2015-04-22 阿塞勒隆制药公司 活化素-actrii拮抗剂及在提高红细胞水平中的用途
KR101871510B1 (ko) * 2008-06-26 2018-06-26 악셀레론 파마 인코포레이티드 액티빈-ａｃｔｒｉｉａ 길항물질을 투약하는 방법 및 치료된 환자의 모니터링
LT3750552T (lt) * 2008-08-14 2023-06-26 Acceleron Pharma Inc. Gdf gaudyklės
ES2613523T3 (es) * 2009-09-09 2017-05-24 Acceleron Pharma, Inc. Antagonistas de ActRIIb y dosificación y usos de los mismos
EP3520805B1 (en) * 2011-10-17 2021-03-10 Acceleron Pharma Inc. Compositions for treating myelofibrosis
AU2013240306A1 (en) * 2012-03-30 2014-10-09 Shire Human Genetic Therapies, Inc. Subcutaneous administration of iduronate- 2-sulfatase
JP6401172B2 (ja) * 2012-10-24 2018-10-10 セルジーン コーポレイション 貧血の治療方法
PT2925864T (pt) * 2012-11-27 2019-02-06 Childrens Medical Ct Corp Elementos reguladores distais de bcl11a como alvo para a reindução de hemoglobina fetal

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014066486A2 (en) * 2012-10-24 2014-05-01 Celgene Corporation Biomarker for use in treating anemia

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
A.G. PIGA ET AL, "ACE-536 increases hemoglobin and decreases transfusion burden and serum ferritin in adults with beta-thalassemia: preliminary results from a phase 2 study", BLOOD, (2014-12-04), vol. 124, no. 21 *
MATTHEW L. SHERMAN ET AL, JOURNAL OF CLINICAL PHARMACOLOGY., US, (2013-09-01), vol. 53, no. 11, doi:10.1002/jcph.160, ISSN 0091-2700, pages 1121 - 1130 *

Also Published As

Publication number Publication date
WO2016183280A1 (en) 2016-11-17
IL284686A (en) 2021-08-31
TW201709927A (zh) 2017-03-16
TWI814187B (zh) 2023-09-01
NZ737043A (en) 2025-02-28
AU2021258087B2 (en) 2023-04-27
JP2018520094A (ja) 2018-07-26
EP3294320A1 (en) 2018-03-21
IL255527B (en) 2021-07-29
JOP20160092B1 (ar) 2023-03-28
HK1251157A1 (zh) 2019-01-25
US20180125928A1 (en) 2018-05-10
AU2021258087A1 (en) 2021-11-25
JP2021191755A (ja) 2021-12-16
KR102640198B1 (ko) 2024-02-23
CN107847562A (zh) 2018-03-27
TW202231294A (zh) 2022-08-16
TN2017000468A1 (en) 2019-04-12
IL284686B (en) 2023-01-01
TWI762444B (zh) 2022-05-01
IL284686B2 (en) 2023-05-01
PH12017502079A1 (en) 2018-06-11
JP6976859B2 (ja) 2021-12-08
IL255527A (en) 2018-01-31
CA2985777A1 (en) 2016-11-17
AU2016261913A1 (en) 2017-11-30
EP3294320A4 (en) 2018-12-26
KR20180006437A (ko) 2018-01-17
MY189601A (en) 2022-02-18

Similar Documents

Publication Publication Date Title
AU2021258087B2 (en) Treatment of beta-thalassemia using ActRII ligand traps
AU2021212084B2 (en) Activin-ActRII antagonists and uses for treating anemia
US20230293634A1 (en) Activin-actrii antagonists and uses for treating bone and other disorders
AU2013334660B2 (en) Methods for treating anemia
CN111050770A (zh) 治疗骨髓增生性肿瘤相关的骨髓纤维化和贫血的方法
CN113604550A (zh) 用于治疗贫血症的生物标志物
HK1248807B (zh) 激活素-actrii拮抗剂及用於治疗贫血症的用途

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)